Literature DB >> 7205383

Imaging the primate adrenal medulla with [123I] and [131I] meta-iodobenzylguanidine: concise communication.

D M Wieland, L E Brown, M C Tobes, W L Rogers, D D Marsh, T J Mangner, D P Swanson, W H Beierwaltes.   

Abstract

An evaluation of radioiodinated meta-iodobenzylguanidine (m-IBG) as an adrenomedullary imaging agent is reported in 15 rhesus monkeys. Scintiscans of the monkey adrenal medulla have been obtained with [123I]- and [m-131I]IBG at 2-6 days after injection. The imaging superiority of m-IBG over its positional isomer, para-iodobenzylguanidine (p-IBG), is documented in both dogs and monkeys. Administration of reserpine, a depletor of catecholamine stores, markedly lowers the [m-131I]-IBG content of the dog adrenal medulla, but the adrenergic blocking agents phenoxybenzamine and propranolol have no effect. Subcellular fractionation of the dog's adrenal medullae reveals that m-IBG is sequestered mainly in the chromaffin storage granules. The results of this study suggest that radioiodinated m-IBG, previously reported to image the primate myocardium, also merits evaluation as a clinical radiopharmaceutical for the adrenal medulla.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7205383

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  33 in total

1.  Norepinephrine spillover during exercise as a novel parameter to evaluate the severity of heart failure.

Authors:  Miyuki Ando; Takeshi Yamamoto; Akihiro Hino; Takashi Sato; Yasuma Nakamura; Masunori Matsuzaki
Journal:  J Nucl Cardiol       Date:  2010-05-26       Impact factor: 5.952

2.  Interaction of metaiodobenzylguanidine with cardioactive drugs: an in vitro study.

Authors:  F Huguet; D Fagret; M Caillet; A Piriou; J C Besnard; D Guilloteau
Journal:  Eur J Nucl Med       Date:  1996-05

3.  Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine.

Authors:  F A Khafagi; B Shapiro; M Fischer; J C Sisson; R Hutchinson; W H Beierwaltes
Journal:  Eur J Nucl Med       Date:  1991

Review 4.  Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature.

Authors:  Arnold F Jacobson; Mark I Travin
Journal:  J Nucl Cardiol       Date:  2015-05-15       Impact factor: 5.952

5.  Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma.

Authors:  Jose Genolla; Trinidad Rodriguez; Pablo Minguez; Ricardo Lopez-Almaraz; Veronica Llorens; Aizpea Echebarria
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-05       Impact factor: 9.236

6.  Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG.

Authors:  Y Nakabeppu; M Nakajo
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

7.  The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience.

Authors:  L Troncone; V Rufini; P Montemaggi; F M Danza; A Lasorella; R Mastrangelo
Journal:  Eur J Nucl Med       Date:  1990

Review 8.  Adverse reactions and drug interactions with radiopharmaceuticals.

Authors:  C B Sampson
Journal:  Drug Saf       Date:  1993-04       Impact factor: 5.606

Review 9.  Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities.

Authors:  A P van Gils; A R van Erkel; T H Falke; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-03

10.  Clinical Implications of Cardiac-MIBG SPECT in the Differentiation of Parkinsonian Syndromes.

Authors:  Dong Hoon Shin; Phil Hyu Lee; Oh Young Bang; In Soo Joo; Kyoon Huh
Journal:  J Clin Neurol       Date:  2006-03-20       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.